[1] Bosch J,Abraldes JG,Berzigotti A,et al. The clinical use of HVPG measurements in chronic liver disease. NatRev Gastroenterol Hepatol,2009,6:573-582.
[2] Bosch J. Vascular deterioration in cirrhosis: thebigpicture. J Clin Gastroenterol,2007,41:S247-S253.
[3] Berzigotti A,Seijo S,Reverter E,et al. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol,2013,7:141-155.
[4] de Franchis R,Baveno VIF. Expanding consensus in portal hypertension: Report of the BavenoVI Consensus Workshop: stratifying risk an dindividualizing care for portal hypertension.J Hepatol,2015,63:743-752.
[5] Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol,2016,13:402-411.
[6] Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology,2007,45:1290-1297.
[7] You MW, Kim KW, Pyo J, et al. A meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension. Ultrasound Med Biol,2017,43:59-68.
[8] Berzigotti A, Seijo S, Arena U, et al. Elastography,spleensize,and platelet countidentify portal hypertension in patients with compensated cirrhosis. Gastroenterology,2013,144:e101.
[9] Abraldes JG, Bureau C, Stefanescu H, et al. Noninvasivetoolsand risk of clinically significant portal hypertension and varices in compensated cirrhosis:The“Anticipate”study. Hepatology,2016.
[10] Ma X, Wang L,Wu H, et al. Spleen stiffness is superior to liver stiffness for predicting esophagealvarices in chronic liver disease: ameta-analysis.PLoS One,2016,11:e0165786.
[11] Colecchia A, Colli A, Casazza G, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis:a prospective study. J Hepatol,2014,60:1158-1164. |
